Cousins: Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study

Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study

Cousins et al., medRxiv, doi:10.1101/2023.02.28.23286515

Cousins et al., Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective.., medRxiv, doi:10.1101/2023.02.28.23286515

Mar 2023 Source PDF

Twitter
Facebook

All Studies Meta

PSM retrospective 898,303 hospitalized COVID-19 patients in the USA, 16,324 on spironolactone, showing lower mortality and ventilation with spironolactone use.

Important missing comments or errors? Let us know.

risk of death, 18.4% lower, RR 0.82, p = 0.004, treatment 390 of 12,504 (3.1%), control 479 of 12,504 (3.8%), NNT 140, odds ratio converted to relative risk, 90 day exposure window, propensity score matching.

risk of death, 11.6% lower, RR 0.88, p = 0.04, treatment 521 of 16,324 (3.2%), control 592 of 16,324 (3.6%), NNT 230, odds ratio converted to relative risk, 180 day exposure window, propensity score matching, primary outcome.

risk of death, 14.5% lower, RR 0.85, p = 0.003, treatment 671 of 20,690 (3.2%), control 783 of 20,690 (3.8%), NNT 185, odds ratio converted to relative risk, 360 day exposure window, propensity score matching.

risk of mechanical ventilation, 16.7% lower, RR 0.83, p < 0.001, treatment 936 of 12,504 (7.5%), control 1,118 of 12,504 (8.9%), NNT 69, odds ratio converted to relative risk, 90 day exposure window, propensity score matching.

risk of mechanical ventilation, 16.7% lower, RR 0.83, p < 0.001, treatment 1,212 of 16,324 (7.4%), control 1,459 of 16,324 (8.9%), NNT 66, odds ratio converted to relative risk, 180 day exposure window, propensity score matching, primary outcome.

risk of mechanical ventilation, 10.2% lower, RR 0.90, p < 0.001, treatment 1,524 of 20,690 (7.4%), control 1,701 of 20,690 (8.2%), NNT 117, odds ratio converted to relative risk, 360 day exposure window, propensity score matching.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Cousins et al., 2 Mar 2023, retrospective, propensity score matching, USA, peer-reviewed, 2 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Spironolactone All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit